Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2016

View Archived Issues

SciFluor Life Sciences presents integrin beta-6/8 antagonists

Bristol-Myers Squibb divulges nonstructural protein 5B inhibitors

NeuPharma patents BTK/EGFR inhibitors

Reata Pharmaceuticals presents nitric oxide production inhibitors

Benralizumab shows significant efficacy in reducing asthma exacerbations in two phase III trials

PCI Biotech announces the dosing of first subject in fimaVACC phase I trial

FDA grants breakthrough therapy designation to Sage Therapeutics' SAGE-547

SAMURAI phase III pivotal trial of lasmiditan achieves both primary and key secondary endpoints

GlycoMimetics begins dosing in first-in-human trial of GMI-1359

First-in-human data reported for INS-1009 in healthy volunteers

Arrowhead Pharmaceuticals begins phase II study of ARC-AAT

Spero Therapeutics joins ENABLE project

Repurposing of carbazole-derived compounds for the treatment of human African trypanosomiasis

Allergan acquires RetroSense Therapeutics

First-in-class covalent inhibitor of CDK12 and CDK13 has anticancer potential

FDA clears IND for phase I trial of Trappsol Cyclo

Aquinox initiates phase III study of AQX-1125 for interstitial cystitis/bladder pain syndrome

First-in-class PRC2 inhibitor from Novartis shows oncolytic activity in vivo

Tonix reports topline results from phase III study of TNX-102 SL for fibromyalgia

Zynerba Pharmaceuticals commences phase II STOP study of synthetic cannabidiol

New approval for Bristol-Myers Squibb's Orencia in Europe

IDMC recommends continuation of phase III trial of cabozantinib in HCC

Futura reports promising topline results from pivotal study of MED-2002 for erectile dysfunction

Aerie submits Rhopressa NDA

Blood-based protein biomarker panel identified for detecting high risk of CRC

MDC, Forschungsverbund Berlin disclose THP2 inhibitors

University of Montreal describes novel PAR4 antagonists

FDA grants orphan drug status to Catalyst's Firdapse in myasthenia gravis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...